SAN DIEGO, June 02, 2025 -- BioAtla, Inc. (Nasdaq: BCAB) (the “Company”), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the...
Arthur Klausner will be a panelist at "The Venture Prognosis - what's driving investment preferences?" at the Life Sciences & Healthcare Venture Summit on October 23, 2007 in NYC
News | 10. 23. 2007
